There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: East Texas Cardiology, PA, Houston, Texas +1 locations
Conditions: Acute Coronary Syndrome
Register for Updates
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686
Recruiting
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The University of Texas, MD Anderson Cancer Center, Houston, Texas
Conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/14/2025
Locations: Neurocare Plus, Houston, Texas
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Local Institution - 0364, Houston, Texas
Conditions: Cancer
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: HCA Houston Healthcare Medical (SCRI), Houston, Texas +1 locations
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2025
Locations: Research Site, Houston, Texas
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579
Recruiting
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Texas Locations, Houston, Texas
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
NCT07047716
Recruiting
The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in people with an indication for PrEP. The primary objective of this study is to evaluate the pharmacokinetics (PK) and the safety and tolerability of intramuscular (IM) every 12 months (Q12M) LEN for PrEP... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/14/2025
Locations: The Crofoot Research Center, Houston, Texas
Conditions: HIV Pre-exposure Prophylaxis
Register for Updates
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks
NCT07116499
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/14/2025
Locations: DM Clinical Research - Bellaire, Houston, Texas
Conditions: Acute Migraine
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
NCT07019883
Recruiting
This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
08/14/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Avian Influenza
Register for Updates
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
NCT06897488
Recruiting
This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
08/14/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
NCT07011771
Recruiting
The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
08/14/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: GBA1 Parkinson Disease
Register for Updates